Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

7 Stocks You Should Be Watching Today

RVNC, BIDU

Some of the stocks that may grab investor focus today are:

Wall Street expects Isle of Capri Casinos (NASDAQ: ISLE) to report its quarterly earnings at $0.54 per share on revenue of $266.77 million. Isle of Capri Casinos shares gained 0.43 percent to $16.42 in after-hours trading.

Baidu Inc (ADR) (NASDAQ: BIDU) lowered its revenue guidance for the second quarter. The company projects Q2 revenue of $2.81 billion to $2.82 billion, versus its earlier forecast of $3.12 billion to $3.19 billion. Baidu shares dropped 5.23 percent to $154.99 in the after-hours trading session.

Analysts expect Bob Evans Farms Inc (NASDAQ: BOBE) to post its quarterly earnings at $0.43 per share on revenue of $345.26 million. Bob Evans Farms shares declined 0.67 percent to close at $44.32 on Monday.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

ImmunoGen, Inc. (NASDAQ: IMGN) announced a private offering of $100 million in convertible senior notes. ImmunoGen shares dipped 11.11 percent to $4.40 in the after-hours trading session.

Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) is expected to report a quarterly loss at $0.52 per share on revenue of $353.98 million. Yingli Green shares surged 4.68 percent to close at $4.25 on Monday.

Revance Therapeutics Inc (NASDAQ: RVNC) reported that its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines (crow's feet) had failed to meet co-primary and other endpoints. Revance Therapeutics shares tumbled 24.20 percent to $13.91 in the after-hours trading session.

Analysts are expecting John Wiley & Sons Inc (NYSE: JW.A) to have earned $0.66 per share in the latest quarter. John Wiley & Sons shares slipped 0.73 percent to close at $51.84 on Monday.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today